hVIVO PLC’s Chief Scientific Officer Andrew Catchpole speaks with Proactive about the company’s latest advancements in human challenge models, including RSV B, HMPV, and Omicron. These models are helping accelerate vaccine and antiviral development by generating fast, reliable proof-of-concept data. Catchpole also outlines hVIVO’s broader expansion into respiratory and non-respiratory diseases.
Watch the full interview on Proactive’s channel for more insights. Don’t forget to like, subscribe, and turn on notifications for the latest biotech updates.
#hVIVO #AndrewCatchpole #RSV #HMPV #Omicron #ChallengeModels #VaccineDevelopment #AntiviralResearch #ClinicalTrials #ProactiveInvestors #PharmaNews #BiotechUpdates #InfectiousDiseaseResearch